Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle.
References
Reichert, J.M. Curr. Pharm. Biotechnol. 9, 423–430 (2008).
Maggon, K. Curr. Med. Chem. 14, 1978–1987 (2007).
DataMonitor. Monoclonal Antibodies Report Part II: Companies—Holding mAbs in Portfolio Promises Protection Against the Looming 2011–2012 Patent Cliff (DataMonitor, New York, 2007).
Humphreys, A. MedAdNews 27, 12–33 (2008).
Reichert, J.M., Rosensweig, C.J., Faden, L.B. & Dewitz, M.C. Nat. Biotechnol. 23, 1073–1078 (2005).
Inbar, D., Hochman, J. & Givol, D. Proc. Natl. Acad. Sci. USA 69, 2659–2662 (1972).
Better, M., Chang, C.P., Robinson, R.R. & Horwitz, A.H. Science 240, 1041–1043 (1988).
Bird, R.E. et al. Science 242, 423–426 (1988).
Abuchowski, A., McCoy, J.R., Palczuk, N.C., van Es, T. & Davis, F.F. J. Biol. Chem. 252, 3582–3586 (1977).
Holliger, P. & Hudson, P.J. Nat. Biotechnol. 23, 1126–1136 (2005).
Harmsen, M.M. & De Haard, H.J. Appl. Microbiol. Biotechnol. 77, 13–22 (2007).
Jain, R.K. Cancer Res. 50, 814s–819s (1990).
Ward, E.S., Gussow, D., Griffiths, A.D., Jones, P.T. & Winter, G. Nature 341, 544–546 (1989).
Yokota, T., Milenic, D.E., Whitlow, M. & Schlom, J. Cancer Res. 52, 3402–3408 (1992).
Jain, R.K. Cancer Res. 47, 3039–3051 (1987).
Jain, R.K. & Baxter, L.T. Cancer Res. 48, 7022–7032 (1988).
Neuwelt, E.A. et al. Cancer Res. 48, 4725–4729 (1988).
Fujimori, K., Covell, D.G., Fletcher, J.E. & Weinstein, J.N. Cancer Res. 49, 5656–5663 (1989).
Stijlemans, B. et al. J. Biol. Chem. 279, 1256–1261 (2004).
Lauwereys, M. et al. EMBO J. 17, 3512–3520 (1998).
Larson, S.M. et al. J. Clin. Invest. 72, 2101–2114 (1983).
Schott, M.E. et al. Cancer Res. 52, 6413–6417 (1992).
Arend, W.P. & Silverblatt, F.J. Clin. Exp. Immunol. 22, 502–513 (1975).
Ward, E.S. et al. Mol. Biol. Cell 16, 2028–2038 (2005).
Woof, J.M. & Burton, D.R. Nat. Rev. Immunol. 4, 89–99 (2004).
Cumber, A.J., Ward, E.S., Winter, G., Parnell, G.D. & Wawrzynczak, E.J. J. Immunol. 149, 120–126 (1992).
King, D.J. et al. Cancer Res. 54, 6176–6185 (1994).
Hudson, P.J. & Souriau, C. Nat. Med. 9, 129–134 (2003).
Shimba, N. et al. FEBS Lett. 360, 247–250 (1995).
Jespers, L., Schon, O., Famm, K. & Winter, G. Nat. Biotechnol. 22, 1161–1165 (2004).
Wörn, A. & Plückthun, A. J. Mol. Biol. 305, 989–1010 (2001).
Sanz, L., Cuesta, A.M., Compte, M. & Alvarez-Vallina, L. Acta Pharmacol. Sin. 26, 641–648 (2005).
Huston, J.S. et al. Proc. Natl. Acad. Sci. USA 85, 5879–5883 (1988).
Skerra, A. & Pluckthun, A. Science 240, 1038–1041 (1988).
Reichert, J.M. & Valge-Archer, V.E. Nat. Rev. Drug Discov. 6, 349–356 (2007).
http://www.fda.gov/cder/biologics/review/abcicen110597r2.pdf
http://www.fda.gov/cder/biologics/review/abcicen110597r1.pdf
http://www.fda.gov/cder/foi/nda/2006/125156s0000_Lucentis_MedR.pdf
Steinbrook, R. N. Engl. J. Med. 355, 1409–1412 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nelson, A., Reichert, J. Development trends for therapeutic antibody fragments. Nat Biotechnol 27, 331–337 (2009). https://doi.org/10.1038/nbt0409-331
Issue Date:
DOI: https://doi.org/10.1038/nbt0409-331
- Springer Nature America, Inc.
This article is cited by
-
A receptor-antibody hybrid hampering MET-driven metastatic spread
Journal of Experimental & Clinical Cancer Research (2021)
-
Expression of antibody fragments in Saccharomyces cerevisiae strains evolved for enhanced protein secretion
Microbial Cell Factories (2021)
-
Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line
Cellular & Molecular Immunology (2021)
-
Generation and functional characterization of a single-chain variable fragment (scFv) of the anti-FGF2 3F12E7 monoclonal antibody
Scientific Reports (2021)
-
Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy
Biotechnology and Bioprocess Engineering (2021)